Risks and Benefits of Continuing Renin-Angiotensin-Aldosterone System Inhibitors in Critically-Ill Patients

被引：0

作者：

Chou, Ruey-Hsing ^{[1
,2
,3
,4
]}

Yang, Shang-Feng ^{[4
,5
]}

Huang, Po-Hsun ^{[2
,4
,6
]}

机构：

[1] Natl Yang Ming Chiao Tung Univ, Dept Crit Care Med, Hsinchu, Taiwan

[2] Natl Yang Ming Chiao Tung Univ, Taipei Vet Gen Hosp, Dept Med, Div Cardiol, Hsinchu, Taiwan

[3] Natl Yang Ming Chiao Tung Univ, Cardiovasc Res Ctr, Hsinchu, Taiwan

[4] Natl Yang Ming Chiao Tung Univ, Inst Clin Med, Hsinchu, Taiwan

[5] Cheng Hsin Gen Hosp, Dept Med, Div Nephrol, Taipei, Taiwan

[6] Natl Yang Ming Chiao Tung Univ, Inst Clin Med, Med, Taipei, Taiwan

来源：

ACTA CARDIOLOGICA SINICA | 2024年 / 40卷 / 02期

关键词：

ACEi; angiotensin-converting enzyme inhibitor; AKI; acute kidney injury; ARB; angiotensin receptor blocker; eGFR; estimated; glomerular filtration rate; ICU; intensive care unit;

D O I：

10.6515/ACS.202403_40(2).20231206B

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We read with interest the letter by Ali Coner et al. responding to our previously published article.1 Dr. Coner suggested drug administration in intensive care units (ICU) should be arranged based on hemodynamic status. They requested us to compare patients who continued renin-angiotensin-aldosterone system (RAAS) inhibitors during ICU stay and those who withdrew in terms of clinical outcome. They also suggested we provide the reasons for withdrawing RAAS inhibitors. Because our institution did not have a standardized protocol guiding

引用

页码：260 / 261

页数：2

共 50 条

[21] Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system
Palmer, BF
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (06): : 585 - 592
[22] Inhibitors of the Renin-Angiotensin-Aldosterone System and Covid-19
Jarcho, John A.
Ingelfinger, Julie R.
Hamel, Mary Beth
D'Agostino, Ralph B.
Harrington, David P.
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (25): : 2462 - 2464
[23] Renin-Angiotensin-Aldosterone System Inhibitors in Covid-19
Haug, Greg
Eapen, Mathew S.
Sohal, Sukhwinder S.
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (24):
[24] COVID-19 and inhibitors of the renin-angiotensin-aldosterone system
Hussain, Musaddique
Jabeen, Qaiser
Ahmad, Fiaz-Ud-Din
Kashif-Ur-Rehman
Fatima, Mobeen
Shaukat, Saira
Majeed, Abdul
Barkat, Muhammad Qasim
Wu, Ximei
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2021, 19 (07) : 815 - 816
[25] New Approaches to Blockade of the Renin-Angiotensin-Aldosterone System: Overview of Regulation of the Renin-Angiotensin-Aldosterone System
Nishiyama, Akira
Kim-Mitsuyama, Shokei
JOURNAL OF PHARMACOLOGICAL SCIENCES, 2010, 113 (04) : 289 - 291
[26] Renin-Angiotensin-Aldosterone System Blockade in Diabetes: Role of Direct Renin Inhibitors
Estacio, Raymond O.
POSTGRADUATE MEDICINE, 2009, 121 (03) : 33 - 44
[27] Diabetes Mellitus and Risks of Dual Blockade of the Renin-angiotensin-aldosterone System
Catala-Lopez, Ferran
Macias Saint-Gerons, Diego
REVISTA ESPANOLA DE CARDIOLOGIA, 2013, 66 (05): : 412 - 415
[28] RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN PHEOCHROMOCYTOMA
SAGAT, T
SASINKA, M
ZVARA, V
PECHAN, J
BLAZICEK, J
INTERNATIONAL JOURNAL OF PEDIATRIC NEPHROLOGY, 1981, 2 (04): : 288 - 288
[29] RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN HYPERTENSION
STREETEN, DH
CLIFT, GV
SCHLETTE.FE
DALAKOS, TS
ANNALS OF INTERNAL MEDICINE, 1968, 68 (05) : 1164 - +
[30] Renin-angiotensin-aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors
Drobni, Zsofia D.
Michielin, Olivier
Quinaglia, Thiago
Zlotoff, Daniel A.
Zubiri, Leyre
Gilman, Hannah K.
Supraja, Sama
Merkely, Bela
Muller, Veronika
Sullivan, Ryan J.
Reynolds, Kerry L.
Pittet, Michael J.
Jain, Rakesh K.
Neilan, Tomas G.
EUROPEAN JOURNAL OF CANCER, 2022, 163 : 108 - 118

← 1 2 3 4 5 →